TCWP’s Aurinia Pharmaceuticals AUPH Stock Holding History

TCWP’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,100	Closed	-$25K	–	379
2022 Q1	$25K	Buy	+2,100	New	+$32.5K	﹤0.01%	634

Other funds holding AUPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

TCWP's AUPH Position: Q2 2022 in Review

TCWP sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2022, closing a stake of 2,100 shares — an estimated $25K sold.

TCWP first reported a position in AUPH in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

TCWP reported no remaining Aurinia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
TCWP sold 2,100 Aurinia Pharmaceuticals shares in Q2 2022, an estimated $25K.
TCWP first reported a position in Aurinia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
TCWP's Aurinia Pharmaceuticals position peaked at $25K in Q1 2022.
199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.